Publication: Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer
Open/View Files
Date
2018
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Metelli, Alessandra, Mohammad Salem, Caroline H. Wallace, Bill X. Wu, Anqi Li, Xue Li, and Zihai Li. 2018. “Immunoregulatory functions and the therapeutic implications of GARP-TGF-β in inflammation and cancer.” Journal of Hematology & Oncology 11 (1): 24. doi:10.1186/s13045-018-0570-z. http://dx.doi.org/10.1186/s13045-018-0570-z.
Research Data
Abstract
GARP (glycoprotein-A repetitions predominant) is a type I transmembrane cell surface docking receptor for latent transforming growth factor-β (TGF-β) that is abundantly expressed on regulatory T lymphocytes and platelets. GARP regulates the availability of membrane-bound latent TGF-β and modulates its activation. For this reason, GARP expression on immune and non-immune cells is involved in maintaining peripheral tolerance. It plays an important role in preventing inflammatory diseases such as allergy and graft versus host disease (GvHD). GARP is also frequently hijacked by cancer cells to promote oncogenesis. This review summarizes the most important features of GARP biology described to date including gene regulation, protein expression and mechanism in activating latent TGF-β, and the function of GARP in regulatory T cell biology and peripheral tolerance, as well as GARP’s increasingly recognized roles in platelet-mediated cancer immune evasion. The promise for GARP-targeted strategy as a novel immunotherapy of cancer is also highlighted.
Description
Other Available Sources
Keywords
TGF-β, GARP, Treg, Immune tolerance, Cancer, Platelets
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service